



LifeTech Scientific Corporation

先健科技公司

(Incorporated in the Cayman Islands with limited liability)
Stock Code: 08122



2012
FIRST QUARTERLY REPORT

CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET (“GEM”) OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”)

GEM has been positioned as a market designed to accommodate companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.

Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.

This report, for which the director(s) (the “Director(s)”) of LifeTech Scientific Corporation (the “Company”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM of the Stock Exchange (the “GEM Listing Rules”) for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this report is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this report misleading.

HIGHLIGHTS

- Turnover for the three months ended 31 March 2012 was approximately RMB42.5 million, representing an increase of approximately 40.3% as compared with the corresponding period in 2011.
- Profit attributable to shareholders of the Company for the three months ended 31 March 2012 was approximately RMB10.5 million, representing an increase of approximately 90.9% as compared with the corresponding period in 2011.
- The Board does not recommend the payment of any dividend for the three months ended 31 March 2012.

UNAUDITED FIRST QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2012

The board of Directors (the “Board”) of the Company is pleased to announce the unaudited consolidated results of the Company and its subsidiaries (the “Group”) for the three months ended 31 March 2012 together with the unaudited comparative figures for the corresponding period in 2011 as follows:

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

	Notes	Three months ended	
		31 March	
		2012 (Unaudited) RMB'000	2011 (Unaudited) RMB'000
Revenue	4	42,460	30,279
Cost of the sales		(8,296)	(6,064)
Gross profit		34,164	24,215
Other income and other gains and losses	5	1,295	859
Selling and distribution expense		(7,995)	(5,235)
Administration expense		(8,324)	(10,270)
Research and development expense	6	(6,372)	(3,418)
Offering expense		—	(1,885)
Profit before tax and change in fair value of convertible redeemable preferred shares	8	12,768	4,266
Change in fair value of convertible redeemable preferred shares		—	3,288
Profit before tax		12,768	7,554
Income tax expense	9	(2,263)	(1,864)
Profit for the period		<u>10,505</u>	<u>5,690</u>
Other comprehensive expense:			
Exchange differences arising on translating foreign operating		(49)	(3)
Total comprehensive (expense)income for the period		<u>10,456</u>	<u>5,687</u>
Profit/(Loss) for the period attributable to:			
Owner of the company		10,466	5,541
Non-controlling interests		39	149
		<u>10,505</u>	<u>5,690</u>
Total comprehensive (expense)income attributable to:			
Owner of the company		10,417	5,538
Non-controlling interests		39	149
		<u>10,456</u>	<u>5,687</u>
Earnings per Share	10		
– Basic (RMB)		0.021	0.022
– Diluted (RMB)		0.021	0.003

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

Attributable to owners of the Company

	Share	Translation	Statutory	Capital	Contribution	Accumulated	Total	Non-	Total Equity	
	capital - common shares									Share premium
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	
At January 1, 2011	3	—	(38)	11,934	(421)	32,531	(44,220)	(211)	3,288	3,077
(Loss) Profit for the period							5,541	5,541	149	5,690
Other comprehensive (expenses) income for the period			(3)					(3)		(3)
Total comprehensive (expenses) income for the period	—	—	(3)	—	—	—	5,541	5,538	149	5,687
Issuance of shares		13,993						13,993		13,993
Conversion of convertible redeemable preferred shares	2	117,154						117,156		117,156
Appropriations				1,477			(1,477)	—		
At March 31, 2011	5	131,147	(41)	13,411	(421)	32,531	(40,156)	136,476	3,437	139,913
At January 1, 2012	32	251,593	691	13,411	(277)	32,531	(33,867)	264,114	3,726	267,840
(Loss) Profit for the period							10,466	10,466	39	10,505
Other comprehensive (expenses) income for the period			(49)					(49)		(49)
Total comprehensive (expenses) income for the period	—	—	(49)	—	—	—	10,466	10,417	39	10,456
At March 31, 2012	32	251,593	642	13,411	(277)	32,531	(23,401)	274,531	3,765	278,296

NOTES :

1. BACKGROUND OF THE COMPANY

The company was incorporated in the Cayman Islands on 17 August, 2006 under the Cayman Islands Companies Law as an exempted company with limited liability. The registered office of the company is located at PO Box 309, Ugland House, Grand Cayman, KY1-1104 Cayman Islands. We have registered a place of business in Hong Kong at 12th Floor, the Lee Gardens, 33 Hysan Avenue, Causeway Bay, Hong Kong and have been registered as a non-Hong Kong company under Part XI of the Hong Kong Companies Ordinance.

The Company is an investment holding company. The principal activities of the Group are development, manufacture and trading of advance interventional medical devices for cardiovascular and neurological diseases.

2. BASIS OF PREPARATION

The unaudited condensed consolidated financial statements of the Group for the three months ended 31 March 2012 have been prepared in accordance with accounting principles in conformity with the International Financial Reporting Standards (“IFRSs”) and the applicable disclosure requirements of the GEM Listing Rules.

3. SIGNIFICANT ACCOUNTING POLICIES

During the three months ended 31 March 2012, the accounting policies adopted are consistent with those followed in the preparation of the Group’s annual financial statements for the year ended 31 December 2011.

The Group has not applied the new and revised IFRSs (listed in the annual report of 2011), which have been issued but not yet effective. The directors of the Company anticipate that the application of the new or revised standards, amendments and interpretations will have no material impact on the consolidated financial statements.

4. REVENUE

	Three months ended 31 March	
	2012 (Unaudited) RMB'000	2011 (Unaudited) RMB'000
Occluder	16,681	15,451
Vena Cava Filter System	12,011	6,475
Stent Graft	7,903	3,738
Others	5,865	4,615
	<u>42,460</u>	<u>30,279</u>

5. OTHER INCOME AND OTHER GAINS AND LOSSES

	Three months ended 31 March	
	2012 (Unaudited) RMB'000	2011 (Unaudited) RMB'000
Government grants	195	216
Rental Income	309	187
Interest income on bank deposits	68	106
Interest on structured deposits	335	—
Net foreign exchange gain/(loss)	240	365
Others	148	(15)
	<u>1,295</u>	<u>859</u>

6. RESEARCH AND DEVELOPMENT EXPENSE

During the three months ended 31 March 2012, the research and development expense amounted to approximately RMB2.3 million is recognised as internally-generated intangible asset since it first meets the recognition criteria listed in the note 3 of annual report of 2011 (The corresponding period in 2011: Nil).

7. SEGMENT INFORMATION

	Three months ended 31 March	
	2012 (Unaudited) RMB'000	2011 (Unaudited) RMB'000
Congenital heart diseases business	21,788	19,913
Peripheral vascular diseases business	20,589	10,350
Surgical vascular diseases business	83	16
	<u>42,460</u>	<u>30,279</u>

8. PROFIT BEFORE TAX AND CHANGE IN FAIR VALUE OF CONVERTIBLE REDEEMABLE PREFERRED SHARES

Profit before tax and change in fair value of convertible redeemable preferred shares has been arrived at after charging (crediting):

	Three months ended 31 March	
	2012 (Unaudited) RMB'000	2011 (Unaudited) RMB'000
Depreciation of property, plant and equipment	1,513	1,106
Staff costs, including Directors' remuneration		
Salaries, wages and other benefits	9,852	5,183
Share-based compensation expense		5,118
Retirement benefits scheme contributions	556	179
	<u>10,408</u>	<u>10,480</u>

9. INCOME TAX EXPENSES

	Three months ended 31 March	
	2012 (Unaudited) RMB'000	2011 (Unaudited) RMB'000
Current tax		
PRC Enterprise Income Tax ("PRC EIT")	2,234	1,837
Deferred tax	29	27
	<u>2,263</u>	<u>1,864</u>

The Company is tax exempted under the laws of the Cayman Islands. New Centre International Limited 新城市國際有限公司 ("New Centre") is subject to Hong Kong Profits Tax rate of 16.5% on profits earned in Hong Kong.

Under the Law of the People's Republic of China on Enterprise Income Tax (the "EIT Law") and Implementation Regulation of the EIT Law, the tax rate of the PRC subsidiaries is 25% except that a major operating subsidiary in the PRC was qualified as High and New Technology Enterprises since 2009 and is entitled to a preferential income tax rate of 15% from 2009 onwards.

For other PRC subsidiaries which are located in Special Economic Zone of the PRC, their applicable income tax rates are 24% and 25% for the three months ended 31 March 2011 and 2012 respectively.

The New EIT Law and its implementing rules also permit qualified small-scale enterprise with low profit margins to enjoy a reduced enterprise income tax rate of 20%. One of the subsidiaries Shenzhen LifeTech Biological Medical Technology Co., Ltd. ("Shenzhen Biological") 深圳市先健生物材料技術有限公司, was entitled to a reduced enterprise income tax rate of 20% as a small-scale enterprise with low profit margins in 2010. The applicable income tax rate is 25% for the three months ended 31 March 2012.

The applicable income tax rate of Lifetech Scientific India Private limited ("Lifetech India") is 30.9% on its taxable profits.

10. EARNING PER SHARE

(a) Basic earnings per share

The calculations of basic earnings per share for the three months ended 31 March 2012 are based on the unaudited condensed consolidated profit of approximately RMB10.5 million attributable to the equity shareholders of the Company for the three months ended 31 March 2012 (three months ended 31 March 2011: approximately RMB5.5 million) and the weighted average number of share in issue for three months ended 31 March 2012 of 500,000,000 (three months ended 31 March 2011: 249,438,279 shares) on the assumption that they have been in issue throughout the periods.

(b) Diluted earnings per share

Diluted earnings per share was not applicable to the three months ended 31 March 2012 as no dilutive events existed during the period.

The diluted earnings per share for the three month ended 31 March 2011 is based on the unaudited consolidated profit of approximately RMB5.5 million, adding back effect of changes in fair value of convertible redeemable preferred shares of approximately RMB3.3 million and exchange gain of approximately RMB1.2 million attributable to the owner of the Company and the adjusted weighted average number of share in issue for the three month ended 31 March 2011 of 397,284,266 shares.

11. DIVIDEND

The Directors do not recommend the payment of an interim dividend for the three months ended 31 March 2012 (The corresponding period in 2011: Nil).

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW

The Group is a developer, manufacturer and marketer of advanced minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. There are three lines of business in our Group, namely congenital and structural heart diseases business (“congenital heart diseases business”), peripheral vascular diseases business and surgical vascular repair business, providing clinically effective and commercially attractive product offerings.

China is our largest market, and sales generated from the Chinese market accounted for approximately 76.3% of our total revenue for the three months ended at 31 March 2012 (The corresponding period in 2011: approximately 70.1%). Our domestic sales realized a 52.6% growth for the three months ended 31 March 2012 as compared to the last corresponding period. Our international market realized a 11.3% growth in sales revenue as compared to the last corresponding period. The increase in revenue was mainly attributable to the rapid growth of sales volume of our primary products along with the expansion of our sales network.

FINANCIAL REVIEW

Summary of the results of the Group for the three months ended 31 March 2012 and the corresponding period in 2011 are as follows:

- Total turnover was approximately RMB42.5 million (Corresponding period in 2011: approximately RMB30.3 million), representing approximately a 40.3% increase as compared to the corresponding period in 2011. The increase was primarily attributable to an increase of approximately RMB10.2 million in revenue from Peripheral vascular diseases business.
- Gross profit was approximately RMB34.2million (Corresponding period in 2011: approximately RMB24.2 million), representing approximately a 41.3% increase as compared to the corresponding period in 2011. The increase was primarily attributable to an increase of approximately RMB12.2 million in revenue.
- The operating profit before tax and before change in fair value of convertible redeemable preferred shares was approximately RMB12.8 million (Corresponding period in 2011: approximately RMB4.3 million), representing approximately an increase of 197.7% as compared to the corresponding period in 2011. The increase was primarily attributable to (1) the increase of revenue; and (2) the decrease of the one time share based compensation amounting to approximately RMB 5.1 million to certain key management of the Group incurred during the first quarter of 2011.
- Net profit attributable to owners of the Company was approximately RMB10.5 million (Corresponding period in 2011: approximately RMB5.5 million), representing approximately a 90.9% increase as compared to the corresponding period in 2011.

BUSINESS OUTLOOK

The Group will continue to rely on its two core businesses namely congenital heart diseases business and peripheral vascular diseases business, as growth potential in the year 2012. The Group will also actively expand its product offering and strengthen its established market position. We expect to obtain SFDA approval for our Cera occluders in the second half of 2012, and launch our Cera in China market upon obtaining approval. We launched our bovine valve in China on February 2012 and for better promotion, a separate sales force and distribution network for our bovine valve in China will be established this year. To facilitate our product launch plans, we will increase investments on physician training programs, and continue to expand our international sales force in Europe, India, Russia and Brazil. We have established a new office in Holland this year, and we believe it will create and reinforce the Lifetech Europe brand and help accelerate our growth in this strategic market.

We will continue to focus on broadening our product portfolio as well as designing innovative products to help capitalize on our growing sales network and infrastructure. Our LAA occluder is expected to complete animal studies and begin human clinical trial studies. Drug-eluting balloons will begin animal testing from second quarter of 2012. We completed clinical trials for Spider PFO occluder in Europe in January, 2012, which is expected to receive CE certification in August, 2012 and then to commercial sales in Europe. Surgical stent grafts and Ankura II stent grafts will start clinical trials in China. Our Cera PFO occluders is planned to be launched in the international market in 2012.

We will evaluate and explore acquisitions, partnerships, alliances and licensing opportunities in the year 2012, to enhance our competitiveness and market position in current key markets as well as selective new markets.

USE OF PROCEEDS GENERATED FROM THE COMPANY'S INITIAL PUBLIC OFFERING

The net proceeds from the Company's issue of new shares at the time of its listing in November 2011, after deduction of related expenses, amounted to approximately HK\$156.6 million. As at 31 March 2012, the company used approximately 6% of the net proceeds, being approximately HK\$1.8 million to enhance market position of core cardiovascular and peripheral vascular devices in key emerging markets, approximately HK\$6.3 million to continue to develop and commercialize pipeline products and approximately HK\$1.8 million to the expansion into key international markets with current and pipeline products. The unused proceeds have been placed in an interest bearing deposit account maintained with a bank in Hong Kong.

DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN THE SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY AND ITS ASSOCIATED CORPORATIONS

As at 31 March 2012, the interests of Directors and chief executives of the Company in the shares and underlying shares of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO")) which were notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests which they are taken or deemed to have under such provisions of the SFO) and required to be entered in the register maintained by the Company pursuant to Section 352 of the SFO or which were required, pursuant to Rules 5.46 to 5.67 of the GEM Listing Rules, to be notified to the Company and the Stock Exchange, were as follows:

(a) Long position in ordinary shares and underlying shares of the Company ("Shares")

Name of Director	Nature of interest	Number of shares	Position	Percentage of the Company's issued share capital
XIE Yuehui	Interest of controlled corporation (<i>Note 1</i>)	101,540,962	Long	20.31%
WU Jianhui	Interest of controlled corporation (<i>Note 2</i>)	87,883,332	Long	17.58%
ZENG Min Frank	Beneficial owner	18,512,143	Long	3.70%
ZHAO Yiwei Michael	Interest of controlled corporation (<i>Note 3</i>)	13,583,333	Long	2.72%
CONG Ning	Beneficial owner	329,771	Long	0.07%
LI Gabriel	Interest of controlled corporation (<i>Note 4</i>)	105,971,990	Long	21.19%

Note 1: These shares are held through Xianjian Advanced Technology Limited, a company wholly owned by Mr. XIE, the chairman and executive director of our Company.

Note 2: These shares are held through GE Asia Pacific Investment Ltd, a company wholly owned by Mr. WU, a non-executive Director of our Company.

Note 3: These shares are held through St.Christopher Investment Ltd., a company wholly owned by Mr. ZHAO, the chief executive officer and executive director of our Company.

Note 4: Among these 105,971,990 Shares, 3,462,592 Shares are registered in the name of Orchid Asia Co-Investment Limited, which is controlled by YM Investment Limited. The remaining 102,509,398 Shares are registered in the name of Orchid Asia III, L.P., which is indirectly controlled by Orchid Asia Group Limited, which is in turn controlled by YM Investment Limited. The entire issued share capital of YM Investment Limited is ultimately held by The Li 2007 Family Trust, which is a BVI discretionary trust established by Ms. Lam Lai Ming, spouse of Mr. Li Gabriel as settlor and Managecorp Limited as trustee on 22 January 2008. The beneficiaries of The Li 2007 Family Trust include family members of Ms. Lam Lai Ming and Mr. Li Gabriel.

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES OF THE COMPANY

As at 31 March 2012, other than the interests of a director or chief executive of the Company as disclosed under the heading "Directors' and chief executive's interests and short position in the shares, underlying shares and debentures" above, the interests and short positions of persons in the shares and underlying shares of the Company as recorded in the register required to be kept by the Company under Section 336 of the SFO were as follows:

Name of Shareholder	Number of shares	Position	Capacity	Percentage of the Company's issued share capital
YM Investment Limited <i>(Note 1)</i>	105,971,990	Long	Interest of controlled corporation	21.19%
Lam Lai Ming <i>(Note 1)</i>	105,971,990	Long	Founder of the Li 2007 Family Trust	21.19%
Managecorp Limited <i>(Note 1)</i>	105,971,990	Long	Trustee	21.19%
Orchid Asia Group Management, Limited <i>(Note 2)</i>	102,509,398	Long	Interest of controlled corporation	20.50%
Orchid Asia Group, Limited <i>(Note 2)</i>	102,509,398	Long	Interest of controlled corporation	20.50%
Orchid Asia III, L.P. <i>(Note 2)</i>	102,509,398	Long	Beneficial owner	20.50%
Xianjian Advanced Technology Limited	101,540,962	Long	Beneficial owner	20.31%
GE Asia Pacific Investments Ltd.	87,883,332	Long	Beneficial owner	17.58%
Themes Investment Partners II GP, L.P.	86,456,000	Long	Interest of controlled corporation	17.29%
Themes Investment Partners II, L.P.	86,456,000	Long	Interest of controlled corporation	17.29%
TIP II General Partner Limited	86,456,000	Long	Interest of controlled corporation	17.29%
Yi Xiqun	86,456,000	Long	Interest of controlled corporation	17.29%
Yu Fan	86,456,000	Long	Interest of controlled corporation	17.29%
Ally Investment Holdings Limited	82,400,000	Long	Interest of controlled corporation	16.48%
Prosperity International	82,400,000	Long	Beneficial owner and person having a security interest in shares	16.48%
Wanhui Limited	82,400,000	Long	Interest of controlled corporation	16.48%

Note 1: Among these 105,971,990 Shares, 3,462,592 Shares are registered in the name of Orchid Asia Co-Investment Limited, which is controlled by YM Investment Limited. The remaining 102,509,398 Shares are registered in the name of Orchid Asia III, L.P., which is indirectly controlled by Orchid Asia Group Limited, which is in turn controlled by YM Investment Limited. The entire issued share capital of YM Investment Limited is ultimately held by The Li 2007 Family Trust, which is a BVI discretionary trust established by Ms. Lam Lai Ming, spouse of Mr. Li Gabriel as settlor and Managecorp Limited as trustee on 22 January 2008. The beneficiaries of The Li 2007 Family Trust include family members of Ms. Lam Lai Ming and Mr. Li Gabriel.

Note 2: Orchid Asia III, L.P. is controlled by OAIH Holdings, L.P., which is in turn controlled by Orchid Asia Group Management Limited, which is in turn controlled by Orchid Asia Group Limited.

Save as disclosed above, as at 31 March 2012, the directors of the Company were not aware of any other person (other than the directors and chief executive of the Company) who had interests or short positions in the shares or underlying shares of the Company as recorded in the register required to be kept by the Company under Section 336 of the SFO.

SHARE OPTION SCHEME

The Company has not granted or issued any option up to 31 March 2012.

DIRECTOR'S RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Apart from the details as disclosed under the heading "Directors' and chief executive's interests and short position in the shares, underlying shares and debentures" above, at no time during the three months were rights to acquire benefits by means of the acquisition of shares in or debentures of the Company granted to any Director or their respective spouse or children under 18 years of age, or were any such rights exercised by them; or was the Company and any of its subsidiaries a party to any arrangement to enable the Directors, or their respective spouse or children under 18 years of age, to acquire such rights in any other body corporate.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SHARES

During the three months ended 31 March 2012, there were no purchases, sales or redemptions of the Company's listed securities by the Company or any of its subsidiaries.

INTERESTS OF THE COMPLIANCE ADVISER

As notified by Piper Jaffray Asia Limited ("PJ"), the Company's compliance adviser, neither PJ nor any of its directors or employees or associates had any interests in the share capital of the Company or any member of the Group (including options or rights to subscribe for such securities) as at 31 March 2012.

DIRECTOR'S INTERESTS IN COMPETING INTERESTS

During the three months ended 31 March 2012 and save as disclosed in the annual report of 2011, the Directors were not aware of any business or interest of the Directors or the management shareholders of the Company and their respective associates (as defined under the GEM Listing Rules) that had competed or might compete with the business of the Group and any other conflicts of interests which any such person had or might have with the Group.

CODE OF CONDUCT REGARDING SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted a code of conduct regarding directors' securities transactions on terms set out in Rules 5.48 to 5.67 of the GEM Listing Rules regarding the directors' securities transactions in securities of the Company. Specific enquiry has been made of all the Directors and the Directors have confirmed that they had complied with such code of conduct from the date of listing of the Company's shares on the Stock Exchange up to 31 March 2012.

AUDIT COMMITTEE

The Company established an audit committee on 22 October 2011 with written terms of reference in compliance with Rule 5.28 of the GEM Listing Rules and paragraph C.3.3 of the CG Code. The Audit Committee consists of three members, the majority of whom are independent non-executive Directors, namely Mr. Liang Hsien Tse Joseph, a Director with the appropriate professional qualifications who serves as the chairman of the audit committee, Mr. Wu Jianhui and Mr. Zhou Gengshen.

The primary duties of the audit committee are to assist our Board in providing an independent view of the effectiveness of our financial reporting process, internal control and risk management system, to oversee the audit process and to perform other duties and responsibilities as assigned by our Board.

The Group's unaudited results for the three months ended 31 March 2012 have been reviewed by the Audit Committee, which was of the opinion that the preparation of such results complied with the applicable accounting standards and requirements and that adequate disclosure has been made.

On behalf of the Board

XIE Yuehui
Chairman

Hong Kong, 11 May 2012

As at the date of this report, the Board comprises Mr. XIE Yuehui and Mr. ZHAO Yiwei Michael being executive directors of the Company; Mr. ZENG Min Frank, Mr. LI Gabriel, Mr. WU Jianhui and Ms. CONG Ning being non-executive directors of the Company; and Mr. LIANG Hsien Tse Joseph, Mr. ZHANG Xingdong, Mr. ZHOU Gengshen being independent non-executive directors of the Company.